Fumaric Acid

Fumaric Acid

SCHEMBL1936048

CCN(C(=O)CC1CCNCC1)c1ccc(Cl)c(Cl)c1Cl.O=C(O)/C=C/C(=O)O

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol

The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
SLC6A4 known ✓ P31645 18/20 0.41
SLC6A2 known ✓ P23975 17/20 0.41
KCNH2 known ✓ Q12809 1/20 0.34
SLC6A3 Q01959 7/20 0.39
CYP2D6 P10635 1/20 0.38
PRMT5 O14744 1/20 0.34
WDR77 Q9BQA1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2398995 0.93 SLC6A4 (0.45) SLC6A4SLC6A2SLC6A3CYP2D6KCNH2
Fumaric Acid SCHEMBL1936204 0.86 SLC6A2 (0.49) SLC6A4SLC6A2SLC6A3CYP2D6KCNH2
Fumaric Acid SCHEMBL2395183 0.86 HRH1 (0.36) SLC6A4SLC6A2SLC6A3
Fumaric Acid SCHEMBL1935822 0.86 SLC6A2 (0.48) SLC6A4SLC6A2SLC6A3CYP2D6KCNH2
SCHEMBL2398246 0.83 SLC6A4 (0.49) SLC6A4SLC6A2SLC6A3CYP2D6KCNH2
Fumaric Acid SCHEMBL1937053 0.82 SLC6A2 (0.45) SLC6A4SLC6A2SLC6A3KCNH2
Hydrochloric Acid SCHEMBL2397591 0.82 SLC6A4 (0.48) SLC6A4SLC6A2SLC6A3CYP2D6KCNH2
Fumaric Acid SCHEMBL1936506 0.80 SLC6A4 (0.41) SLC6A4SLC6A2SLC6A3PRMT5WDR77
Fumaric Acid SCHEMBL1936479 0.79 SLC6A4 (0.41) SLC6A4SLC6A2SLC6A3
SCHEMBL2394229 0.78 SLC6A2 (0.46) SLC6A4SLC6A2SLC6A3CYP2D6KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110212997-A1 PIPERIDINE-4-ACETAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2011-09-01 US disclosed
EP-2331505-A2 PIPERIDINE-4-ACETAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NeuroSearch A/S (DK) 2011-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212997-A1 PIPERIDINE-4-ACETAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS SLC18A2, SLC6A2, SLC18A3 SLC6A4 4/4885SLC6A2 2/4885KCNH2 1085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.